title: Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
abstract: In order to develop a sensitive audiometric protocol for identifying ototoxicity in children, a retrospective study of 16 children treated with cisplatin and/or carboplatin was performed. Audiometric testing was done by means of pure-tone threshold audiometry (PTA), high-frequency audiometry (HFA), and distortion product otoacoustic emissions (DPOAEs). Cisplatin caused a sensorineural high-frequency hearing loss in the study group compared to the controls (p < 0.01). Sixty-six percent of the cisplatin patients had a grade 2 or 3 ototoxicity. However, ototoxicity was not found in the patients treated with carboplatin. An excellent correlation was found between DPOAE levels and results obtained by audiometry (r = 0.82). Patients exposed to cisplatin are at significant risk for the development of drug-induced sensorineural hearing loss. Because of the several advantages of DPOAEs (noninvasive, objective, rapid, easy to use, sensitive) this method should be added in the audiological follow-up in infants and toddlers.
authors.affiliation: ENT Department, Department of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent, Belgium. ingeborg.dhooge@ugent.be
authors.forename: Ingeborg
authors.initials: I
authors.lastname: Dhooge
authors.forename: Catharina
authors.initials: C
authors.lastname: Dhooge
authors.forename: Sven
authors.initials: S
authors.lastname: Geukens
authors.forename: Bieke
authors.initials: B
authors.lastname: De Clerck
authors.forename: Eddy
authors.initials: E
authors.lastname: De Vel
authors.forename: Bart M
authors.initials: BM
authors.lastname: Vinck
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects*; D016190:Carboplatin / Q000009:adverse effects* / Q000494:pharmacology; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects / Q000502:physiology*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin